2 studies found for:    mk-2206 endometrial
Show Display Options
Rank Status Study
1 Active, not recruiting PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Condition: Endometrial Cancer
Intervention: Drug: MK-2206
2 Active, not recruiting Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years